ACOR Financial Facts

Total other expense (net): -3.57M
Net loss per share-basic (earnings per share): 0.02
See Full Income Statement

Current portion of convertible notes payable: 1.14M
Additional paid-in capital: 783.13M
See Full Balance Sheet

Acorda Therapeutics, Inc. (ACOR) Earnings

  |   Expand Research on ACOR
Next EPS Date 10/30/15 *Est. EPS Growth Rate -26.2% *Last Qtr.
Average EPS % Beat Rate +194.5% Revenue Growth Rate +8.6% *Last Qtr.
Average % Move 1-Wk after EPS -1.8% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
7/30/15 Q215 $0.31$0.17 +$0.14$105.5M$110.84M N/A Details
2/12/15 Q414 $0.46$0.14 +$0.32$117.9M$110.8M N/A Details
4/30/15 Q115 $0.15$0.14 +$0.01$99.85M$100.2M N/A Details
10/30/14 Q314 $0.28$0.05 +$0.23$106M$94.7M N/A Details
7/31/14 Q214 $0.42$0.15 +$0.27$97.13M$91.4M N/A Details
11/4/11 Q311 $0.40$0.73 -$0.33$93.03M$90.78M N/A Details
10/31/13 Q313 $0.36$0.13 +$0.23$84.92M$90.01M N/A Details
2/13/14 Q413 $0.32$0.18 +$0.14$92.59M$89.96M N/A Details